Skip to content

Biohaven BHVN Total Liabilities

Total Liabilities at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$48.99M+24.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$26.09M+60.8%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$212.82M-19.4%
uniQure logo
uniQureQURE
$629.36M+10.1%
Roivant Sciences logo
Roivant SciencesROIV
$416.28M+66.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$41.99M-20.9%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's total liabilities?
Biohaven (BHVN) reported total liabilities of $336.91M in Q1 2026.
How has Biohaven's total liabilities changed year-over-year?
Biohaven's total liabilities increased by 68.9% year-over-year, from $199.45M to $336.91M.
What is the long-term trend for Biohaven's total liabilities?
Over 4 years (2021 to 2025), Biohaven's total liabilities has grown at a 70.4% compound annual growth rate (CAGR), from $47.37M to $399.38M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.